Tumor necrosis factor-alpha and interferon-gamma induce inflammasome-mediated corneal endothelial cell death

Purpose: Chronic corneal endothelial cell (CEC) loss results in corneal edema and vision loss in conditions such as pseudophakic bullous keratopathy (PBK), Fuchs' dystrophy, and corneal graft failure. Low CEC density has been associated with an elevation of intraocular pro-inflammatory cytokines such as tumor necrosis factor (TNF)-alpha and interferon (INF)-gamma. These cytokines are capable of triggering pyroptosis, a programmed cell death mechanism mediated by the inflammasome, prompting the activation of the pro-inflammatory cytokine interleukin (IL)-1 beta, the perpetuation of inflammation, and subsequent damage of corneal endothelial tissue. Therefore, the purpose of this study was to determine the deleterious contribution of the inflammasome and pyroptosis to CEC loss. Methods: CECs from human donor corneas were treated ex vivo with TNF-alpha and IFN-gamma for 48 h. Levels of caspase-1 and IL-1 beta were then assayed by ELISA, and the expression of caspase-1 and gasdermin-D (GSDM-D) were confirmed by immunofluorescence. Endothelial cell damage was analyzed by a lactate dehydrogenase (LDH) release assay, and oxidative stress was determined by measuring the levels of reactive oxygen species (ROS) in the culture media. Results: Inflammasome activation and oxidative stress were elevated in CECs following exposure to TNF-alpha and IFN-gamma, which resulted in cell death by pyroptosis as determined by LDH release which was inhibited by the caspase-1 inhibitor Ac-YVAD-cmk. Conclusion: CEC death is induced by the pro-inflammatory cytokines TNF-alpha and IFN-gamma, which contribute to inflammasome activation. Moreover, the inflammasome is a promising therapeutic target for the treatment of chronic CEC loss.

Automated summary

Chronic corneal endothelial cell loss, induced by pro-inflammatory cytokines like TNF-alpha and IFN-gamma, is associated with inflammasome activation and subsequent pyroptosis. Inhibition of inflammasome presents a promising therapeutic target for the treatment of chronic CEC loss.